Deep sequencing of an AML cell line, with and without p53, treated with vehicle control, BETi, MDM2i, or a drug combination

Gene expression changes were compared in human OCI-AML3 cells, with or without p53 knock down, that were treated with DMSO (vehicle control), the BET inhibitor CPI-203, the MDM2 inhibitor Nutlin-3a, or a combination of both drugs. compared. Method: OCI-AML3 cells were transduced with either empty vector or vector expressing an shRA targeting p53. Cells were then treated for 24 hrs with either DMSO, CPI-203, Nutlin-3a or a combination of both drugs. PolyA mRNA was extracted, in triplicate, then sequenced with an Illumina NextSeq 500 sequencer. Sequence reads passing the quality control filters were aligned using Tophat2 and then analysed with Cufflinks. Keywords: Expression profiling by high throughput sequencing polyA mRNA profiles from drug-treated human OCI-AML3 cells with or without p53 were generated, in triplicate, using an Illumina NextSeq500 sequencer.

本数据集对经不同方式处理的人OCI-AML3细胞的基因表达变化进行了比较：受试细胞分为存在p53敲低与不存在p53敲低两组，每组均分别接受四种处理：二甲基亚砜（DMSO，溶剂对照）、BET抑制剂（BET inhibitor）CPI-203、MDM2抑制剂（MDM2 inhibitor）Nutlin-3a，以及两种药物联合处理。

实验方法：将OCI-AML3细胞转导空载体，或转导表达靶向p53的shRA的载体。随后将各组细胞分别用DMSO、CPI-203、Nutlin-3a或两种药物联合处理24小时。提取三倍重复的聚腺苷酸（polyA）mRNA，使用Illumina NextSeq 500测序仪进行测序。通过质量控制过滤的序列读数采用Tophat2进行序列比对，后续通过Cufflinks完成表达分析。

关键词：高通量测序表达谱分析；从经药物处理的、存在或不存在p53敲低的人OCI-AML3细胞中获得的聚腺苷酸mRNA谱，所有样本均设置三次生物学重复，采用Illumina NextSeq500测序仪完成测序。